Optimi Health Completes Largest Legal Harvest of Psilocybin in Canada’s History

Optimi Health Corp. is a homegrown Canadian company producing natural, scalable and accessible psychedelic and functional mushrooms and synthetic formulations for transformational human experiences. The company is on Health Canada’s list of approved suppliers under the Special Access Program (SAP), which allows medical practitioners access to Schedule 3 controlled substances like psilocybin on a case-by-case emergency basis.

On September 8, Optimi Health reported that it has finished what it thinks to be the biggest legal natural psilocybin harvest in Canadian history. Health Canada has granted the company permission to cultivate and distribute organic, EU-GMP quality psilocybin and other psychedelic drugs, most notably MDMA, as well as functional mushrooms, with an emphasis on the health and wellness industries.

The company is happy to report that its investment in cutting-edge environmental controls and facility cultivation operations has resulted in a commercially harvested yield of more than 150 kg of Panaeolus cyanescens and Psilocybe cubensis. This harvest comes after the company’s first formal one, which took place on May 27 and yielded many strains of psilocybin for lab testing and early supply agreements.

All Optimi Health mushroom products are grown from the company’s industry-leading psilocybin genetic bank and are produced in clean rooms that comply with EU-GMP standards to ensure sterile cultivation. After harvest, the mushrooms go through nearly 300 different analytical tests.

The company will start distributing the harvested quantities to fulfil supply agreements signed recently with various industry partners and authorized research entities worldwide after they have been examined and tested internally and by a licenced third-party lab per Optimi’s strict product specification and quality assurance standards.

“By controlling and tracking all of the inputs digitally, we are able to consistently grow psilocybin-containing mushrooms at a much higher potency to maximize the amount of naturally occurring psilocybin within the mushroom,” said Bryan Safarik, Chief Operations Officer of Optimi Health.

To guarantee that the natural psilocybin doesn’t degrade too much, all extra stock from the harvest will be securely housed in Optimi’s Level 8 Security Vault.

The product will be used by Optimi to complete its organically derived psilocybin offerings this fall. Additionally, the company will use the mushrooms to improve its on-site extraction techniques. The company is striving to provide a number of planned phase 1 and phase 2 clinical trials to gather the necessary human safety data in Canadians in good health and, eventually, patients with depression, anxiety, and PTSD.

The company’s global innovation strategy is fundamentally based on supplying psilocybin products that are secure and authorized by the federal government to markets other than encapsulated biomass.

Optimi Health Signs With Avida Global First Contract for the Supply of Mushrooms Abroad

On September 7, Optimi Health disclosed that it has entered into a partnership with Avida Global. This private British company produces premium health and wellness goods for the global medical and health sectors, including nutraceuticals and medicinal cannabis oils.

Optimi will provide Avida with various Optimi Life functional mushroom supplement formulations as part of its first significant international distribution agreement. The company’s manufacturing and white-labeling branch, Avida Labs, will market the supplements worldwide to clients and business partners.

Avida will only offer functional mushroom products from Optimi in the UK, the EU, Switzerland, India, Japan, Indonesia, Thailand, and Israel.

The agreement’s conditions also permit the potential sale of psilocybin mushrooms using the same distribution channels. This is done to adapt to the shifting demands of global markets.

The international agreement with Optimi Health represents a significant advancement for Avida in plant-based therapeutics. Paul Parkinson reported that the Managing Director and Head of UK Operations of Avida Global agreed it would benefit both businesses and increase their exposure.

For more information on Optimi Health Corp., please visit this link.


422 Richards Street Suite 170


comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No THE 2 SIDE STORY journalist was involved in the writing and production of this article.